EUVIMEDEUVIMED entdecken
Crossref

Pharmacoepidemiological analysis of antiplatelet drug consumption in outpatient practice

Dariya V Ivanova, Ayrat Usmanovich Ziganshin, Rustem N Khairullin, Liliya Eugenevna Ziganshina iD

International Journal of Risk & Safety in Medicine · 2025

DOI: 10.1177/09246479251409027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Risk & Safety in Medicine, 2025. Verfasst von Dariya V Ivanova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Kazan State Medical University, Kazan, Russia. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Acute Coronary Syndrome, Ambulatory Care, Drug Utilization. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute coronary syndrome remains a leading cause of mortality, making antiplatelet therapy crucial for the treatment and secondary prevention of this condition.

Purpose

We aimed to analyze consumption of antiplatelet drugs in the outpatient segment of the pharmaceutical market in the Republic of Tatarstan in 2018 and 2023. Research Design We conducted a descriptive study based on sales data for antiplatelet drugs from two major suppliers. Data Collection and Analysis Consumption was calculated in milligrams and defined daily doses. To assess therapy coverage, we calculated standard course doses for dual antiplatelet therapy and monotherapy based on clinical guidelines.

Results

During the study period, we identified a significant increase in the consumption of all antiplatelet drugs. Acetylsalicylic acid consumption doubled. Among P2Y 12 -receptor inhibitors, clopidogrel showed the highest absolute increase (2.5 times), while ticagrelor (3.2 times) and prasugrel (4 times) showed the highest relative growth rates. The estimated number of patients who could have been treated with the sold volumes of antiplatelet drugs in 2018 was 15.4 times, and in 2023 was 35.2 times higher than the official number of registered ACS patients.

Conclusions

We observe a significant increase in outpatient antiplatelet drug consumption, reflecting current trends toward expanding indications and increasing therapy duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsAcute Coronary SyndromeAmbulatory CareDrug UtilizationHumansPharmacoepidemiologyTicagrelorAspirinPrasugrel HydrochlorideClopidogrelOutpatients

Stichwörter der Autor:innen

Republic of Tatarstanacetylsalicylic acidantiplatelet therapyclopidogreldefined daily dosepharmacoepidemiologyticagrelor

Substanzen

Platelet Aggregation InhibitorsTicagrelorAspirinPrasugrel HydrochlorideClopidogrel

Autor:innen und Institutionen

  • Department of Pharmacology, Kazan State Medical University, Kazan, Russia.
  • Interregional Clinical Diagnostic Center, Kazan, Russia.
  • Department of General and Clinical Pharmacology, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN University), Moscow, Russia.

ORCID-Profile: Liliya Eugenevna Ziganshina

Zitieren

APA

Ivanova, D. V., Ziganshin, A. U., Khairullin, R. N., & Ziganshina, L. E. (2025). Pharmacoepidemiological analysis of antiplatelet drug consumption in outpatient practice. International Journal of Risk & Safety in Medicine. https://doi.org/10.1177/09246479251409027

Vancouver

Ivanova DV, Ziganshin AU, Khairullin RN, Ziganshina LE. Pharmacoepidemiological analysis of antiplatelet drug consumption in outpatient practice. International Journal of Risk & Safety in Medicine. 2025. doi:10.1177/09246479251409027

BibTeX
@article{Ivanova2025,
  author = {Ivanova, Dariya V and Ziganshin, Ayrat Usmanovich and Khairullin, Rustem N and Ziganshina, Liliya Eugenevna},
  title = {Pharmacoepidemiological analysis of antiplatelet drug consumption in outpatient practice},
  journal = {International Journal of Risk & Safety in Medicine},
  year = {2025},
  doi = {10.1177/09246479251409027}
}
Kostenlos starten →